Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
The identification of novel therapies, new strategies for combination of therapies, and repurposing of drugs approved for other indications are all important for continued progress in the fight against lung cancers. Antibodies that target immune checkpoints can unmask an immunologically hot tumor fr...
Guardado en:
Autores principales: | Keller J Toral, Mark A Wuenschel, Esther P Black |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9d7801d876b04b58a06872bac8a15f68 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
por: Tomohiro Takehara, et al.
Publicado: (2021) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021) -
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kensuke Kojima, et al.
Publicado: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)